Kusuhara Hirohisa, Itani Yoshihito, Isogai Noritaka, Tabata Yasuhiko
Kinki University School of Medicine, Department of Plastic and Reconstructive Surgery, Osaka, Japan.
J Hand Surg Eur Vol. 2011 Jul;36(6):455-60. doi: 10.1177/1753193411402761. Epub 2011 Mar 29.
We undertook a randomized controlled trial of subzone II fingertip amputations, comparing standard treatment with topical application of gelatin microspheres prepared with basic fibroblast growth factor (b-FGF) to provide a slow, sustained release of b-FGF with microsphere degradation. Forty-eight digits from 42 patients were randomized into the two study arms. The microspheres were applied as a paste on exposed tissue surfaces, whereas standard treatment was without any topical treatment. Patients were treated either with microsurgical revascularization or by simple composite graft, based on the surgeon's clinical decision. Tissue survival of the replanted fingertips was measured by a blinded evaluator 3 weeks postoperatively. A modest improvement in survival was seen with b-FGF-microsphere application for both revascularized and composite grafted fingertips, though this did not achieve statistical significance. Whether the slow release of b-FGF through a bioresorbable carrier gives any improvement in outcome in patients with subzone II fingertip amputations is unproven.
我们开展了一项关于Ⅱ区指尖离断伤的随机对照试验,比较标准治疗与局部应用含有碱性成纤维细胞生长因子(b-FGF)的明胶微球,该微球可随着降解缓慢、持续释放b-FGF。42例患者的48根手指被随机分为两个研究组。微球以糊剂形式涂覆于暴露的组织表面,而标准治疗不进行任何局部治疗。根据外科医生的临床判断,患者接受显微外科血管重建或单纯复合组织移植治疗。术后3周由一位不知情的评估者测量再植指尖的组织存活情况。对于接受血管重建和复合组织移植的指尖,应用b-FGF微球后存活情况有一定改善,但未达到统计学意义。通过生物可吸收载体缓慢释放b-FGF是否能改善Ⅱ区指尖离断伤患者的预后尚无定论。